About Hyperway

Aiming at the corporate goal of “Develop Quality Medicines, Innovate in China”, Hyperway Pharma has assembled an international, professional core R&D team with forward-looking strategic vision and resources under the guidance of unmet clinical needs and the drive of innovation. Focused on developing First-in-Class (FIC) and Best-in-Class (BIC) targeted innovative drugs, Hyperway Pharma strives to become an internationally influential innovative biopharmaceutical enterprise, making continuous contributions to human health.

Hyperway Pharma concentrates on oncology, pain management, and central nervous system disorders. The company strategically diversifies its R&D pipeline, advances projects with high quality, and systematically builds specialized brain-penetrant drug development platforms, achieving significant breakthroughs. The company has filed over 70 domestic and international patent applications, identified 11 PCCs, and has 5 innovative drug projects currently in clinical trials. Multiple research achievements have been featured at international academic conferences, earning substantial recognition globally.

Culture

Corporate Culture

  • Objectives

    Leading in concept, leading in technology, leading in strategy

  • Philosophy

    Embrace all advances !

    Attract all talents !

    Benefit all people !

    Achieve all our best !

  • Values

    Innovation, Purpose-Driven, Gratitude, Learning, Teamwork, Passion

  • Vision

    Made in China! Innovated in China!

2019

Chengdu Hyperway Pharmaceutical founded.

Angel investment completed.

2020

Shenzhen Hyperway Pharmaceutical founded.

Series Pre-A financing completed.

2021

Series A financing completed.

2022

Clinical trial for HBW-3220 approved.

Phase I clinical trial for HBW-3220 in China launched.

Clinical trial for HBW-3210 approved.

2023

Clinical trial for HBW-004285 approved.

Phase I clinical trial for HBW-3210 in China launched.

Phase I clinical trial for HBW-004285 in China launched.

2024

Series A+ financing completed.

2025

Series B financing completed.

PhaseⅡclinical trial for HBW-004285 in China launched.

PhaseⅢclinical trial for HBW-3220 in China launched.

PhaseⅠ/Ⅱclinical trial for HBW-012336 in China launched.

PhaseⅠ/Ⅱclinical trial for HBW-012462 in China launched.

Honors & Certifications

Management Team

  • Yingfu Li, Ph.D

    Founder, Chairman & CEO

    Bayer's Research Centers (German Headquarters, Japan, and the USA), extensively involved in drug discovery and development for over ten years. Key inventor for several clinical candidates, including 1st Syk Inhibitor BAY61-3606.

    Brilliant Pharmaceutical Research Institute, President. Achieved >60 new products launched in China and advanced several new drugs into clinical trials.

    Chempartner (Chengdu). Established worldwide CRO business and partnership with large pharmaceuticals.

    AMRI, Yangzijiang Pharmaceutical.

    Over 90 patent applications & 30 publications worldwide.

    West China University of Medical Sciences, Ph.D. in Medicinal Chemistry.

    Bayer Research Center (Germany), awarded postdoctoral fellowship.

  • Ning Lee, Ph.D

    Senior Vice President,Target Biology,Business Development

    Bristol-Myers Squibb, held positions of increasing responsibility and advanced multiple drug discovery programs through preclinical stages

    Chiron (now Novartis), with Professor (Rusty) Lewis Williams, entrepreneur and member of US National Academy of Sciences (NAS)

    Harvard University, Postdoctoral fellow with Professor Jack Strominger, Lasker Awardee, and member of US NAS

    Brandeis University, Ph.D. in Molecular and Cell Biology

    National Taiwan University, B.S. in Agricultural Chemistry

    Over 15 patent applications & publications, rich experience in Immunology, Oncology, CNS, CV & Metabolic diseases

Advisory Board

  • Yushe Yang

    Professor of shanghai Institute of Materia Medica, Chinese Academy of Sciences

    Professor of shanghai Institute of Materia Medica, Chinese Academy of Sciences

    The major research field of Prof. Yang’s group covers antibacterial agent, antidiabetic drug and antithrombotic drug discovery, new method and new process for drug synthesis, and the group has rich experience in innovative drug research. In 2009, the first new fluoroquinolone antibacterial agent with independent intellectual property―antofloxacin hydrochloride was successfully developed by Yang’s group. It is recognized as the landmark achievement of the “Key New Drug Creation and Manufacturing Program” of the “Eleventh Five-year Plan” in China, filling up the innovation gap in this field in more than 40 years. Antofloxacin hydrochloride has a better safety profile and pharmacokinetic property and its successful marketing is of great importance to the promotion of national innovative drug research and self-innovative ability in China.

    Prof. Yang won the 2013 China Pharmacy Development Award-Innovative Drugs Award-Outstanding Achievement Award. In 2010, he won the title of “2007-2009 Advanced Worker in Shanghai (Model Worker)”. In 2010, he won the IBC China Drug Discovery of the Year Award.

  • Fen-er Chen

    Academician of Chinese Academy of Engineering

    Academician of Chinese Academy of Engineering

    The Fen-er Chen Group Honors

    1、Chinese Chemical Society-Sci Finder Award for Creative Work in Synthetic Organic Chemistry in 2011

    2、National excellent scientific and technological workers in 2010

    3、ten elites of science and technology in Shanghai in 2009

    4、Second prize of Shanghai invention patents in 2008

    5、Second prize of National Science and Technology Progress Award in 2007

    6、Prize for scientific and technological progress in medical sciences and materia medica in Ho Leung Ho Lee Foundation in 2006

    7、The invention of Chinese entrepreneurship Award in 2006

    8、Award for outstanding Chinese patented invention in world intellectual property organization in 2006

    9、ten staffs of excellence and innovation in Shanghai in 2006

    10、Shanghai inventor Award in 2006

    11、Wu Yunchu Award for chemical talents incentive fund in 2005

    12、Second prize of national technological invention Award in 2005

    13、Award for outstanding Chinese patented invention in world intellectual property organization in 2005

    14、First Prize for Ministry of Education Science and Technology Progress Award in 2004

    15、First prize for invention patent IN Shanghai in 2004

    16、China Pharmacy Development Award Outstanding Young Scholar Award in 2004

    17、First prize for scientific and technological progress in Shanghai in 2003

    18、Special government allowances of the State Council in 1993

  • Wenhao Hu

    Professor of Sun Yat-sen University

    Professor of Sun Yat-sen University

    Representative papers

    1. Dan Zhang, Jun Zhou, Fei Xia, Zhenghui Kang, and Wenhao Hu*, Bond cleavage, fragment modification and reassembly in enantioselective three-component reactions, Nat Commun. 2015, 6, 5801.

    2. Xiaochu Ma, Jun Jiang, Siying Lv, Wenfeng Yao, Yang Yang, Shunying Liu,* Fei Xia, and Wenhao Hu*, An Ylide Transformation of Rhodium(I) Carbene: Enantioselective Three-Component Reaction through Trapping of Rhodium(I)-Associated Ammonium Ylides by β-Nitroacrylates, Angew. Chem. Int. Ed. 2014, 53, 13136-13139.

    3. Dan Zhang, Huang Qiu, Liqin Jiang,* Fengping Lv, Chaoqun Ma, and Wenhao Hu*,. Enantioselective Palladium(II) Phosphate Catalyzed Three-Component Reactions of Pyrrole, Diazoesters, and Imines. Angew. Chem. Int. Ed. 2013, 125, 13598-13602.

    4. Shikun Jia, Dong Xing, Dan Zhang, and Wenhao Hu*, Catalytic Asymmetric Functionalization of Aromatic C-H Bonds by Electrophilic Trapping of Metal-Carbene-Induced Zwitterionic Intermediates, Angew. Chem. Int. Ed. 2014, 53, 13098-13101.

    5. Changcheng Jing, Dong Xing, Yu Qian, Taoda Shi, Yun Zhao, and Wenhao Hu*, Diversity-Oriented Three-Component Reactions of Diazo Compounds with Anilines and 4-Oxo-Enoates. Angew. Chem. Int. Ed. 2013, 52, 9289-9292.

    6. Xin Guo, and Wenhao Hu*, Novel Multicomponent Reactions via Trapping of Protic Onium Ylides with Electrophiles, Acc. Chem. Res. 2013, 46, 2427-2440.

    7. Jun Jiang, Xiaoyu Guan, Shunying Liu, Baiyan Ren, Xiaochu Ma, Xin Guo, Fengping Lv, Xiang Wu, and Wenhao Hu*, Highly Diastereoselective Multicomponent Cascade Reactions: Efficient Synthesis of Functionalized 1-Indanols, Angew. Chem. Int. Ed. 2013, 52, 1539-1542.

    8. Huang Qiu, Ming Li, Li-Qin Jiang, Feng-Ping Lv, Li Zan, Chang-Wei Zhai, Michael P. Doyle, and Wen-Hao Hu*, Highly enantioselective trapping of zwitterionic intermediates by imines, Nature Chem. 2012, 4, 733-739.

    9. Jun Jiang, Hua-Dong Xu, Jian-Bei Xi, Bai-Yan Ren, Feng-Ping Lv, Xin Guo, Li-Qin Jiang, Zhi-Yong Zhang, and Wenhao Hu*, Diastereoselectively Switchable Enantioselective Trapping of Carbamate Ammonium Ylides with Imines, J. Am. Chem. Soc. 2011, 133, 8428-8431.

    10. Xiaoyu Guan, Liping Yang, and Wenhao Hu*, Cooperative Catalysis in Multicomponent Reactions: Highly Enantioselective Synthesis of γ-Hydroxyketones with a Quaternary Carbon Stereocenter, Angew. Chem. Int. Ed. 2010, 49, 2190-2192.